Sepsis, low platelet nadir at mobilization and previous IFN use predict stem cell mobilization failure in patients with multiple myeloma

References

• Siena S, Bregni M, Brando B, et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte–macrophage colony-stimulating factor. Blood 1989; 74: 1905–14
   PubMed Web of Science ®Google Scholar
• Alegre A, Tomas JF, Martinez-Chamorro C, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 1997; 20: 211–17
   PubMed Web of Science ®Google Scholar
• Desikan KR, Barlogie B, Jagannath S, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16: 1547–53
   PubMed Web of Science ®Google Scholar
• Haas R, Möhle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–94
   PubMed Web of Science ®Google Scholar
• Remes K, Matinlauri I, Grenman S, et al. Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and post-transplant hematopoietic recovery. J Hematother 1997; 6: 13–19
   PubMedGoogle Scholar
• Bensinger WI, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony-stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825–31
   PubMed Web of Science ®Google Scholar
• Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547–55
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Hegenbart U, Haas R, et al. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691–7
   PubMed Web of Science ®Google Scholar
• Watts MJ, Sullivan AM, Jamieson E, et al. Progenitor cell mobilisation after low-dose cyclophosphamide and G-CSF: an analysis of progenitor cell quality and factors predicting for these parameters in 101 pre-treated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535–46
   PubMed Web of Science ®Google Scholar
• Dreger P, Kloss M, Petersen B, et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cells but not of bone marrow grafts. Blood 1995; 86: 3970–8
   PubMed Web of Science ®Google Scholar
• Drake M, Ranaghan L, Morris TCM, et al. Analysis of the effect of prior chemotherapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997; 98: 745–9
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–23
   PubMed Web of Science ®Google Scholar
• Johnsen HE. Report from a Nordic workshop on CD34+ cell analysis: technical recommendations for progenitor cell enumeration in leukapheresis from multiple myeloma patients. J Hematother 1995; 4: 21–8
   PubMedGoogle Scholar
• Schots R, Van Riet I, Damiaens S, et al. The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis. Bone Marrow Transplant 1996; 17: 509–15
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Winkler J, Waller C, et al. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Bone Marrow Transplant 1997; 19: 529–37
   PubMed Web of Science ®Google Scholar
• Koumakis G, Vassilomanolakis M, Hatzichristou H, et al. Predictive factors affecting mobilization and peripheral blood stem cell (PBSC) collection using single apheresis (SA) for rescuing patients after high-dose chemotherapy (HD.CHE) in various malignancies. Bone Marrow Transplant 1996; 18: 1065–72
   PubMed Web of Science ®Google Scholar
• Clark RE, Brammer CG. Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998; 22: 859–63
   PubMed Web of Science ®Google Scholar
• Marit G, Thiessard F, Faberes C, et al. Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study. Leukemia 1998; 12: 1447–56
   PubMed Web of Science ®Google Scholar
• Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588–96
   PubMed Web of Science ®Google Scholar
• Prince HM, Imrie K, Sutherland DR, et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br J Haematol 1996; 93: 142–5
   PubMed Web of Science ®Google Scholar
• Kotasek D, Shepherd KM, Sage RE, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11–17
   PubMed Web of Science ®Google Scholar
• Tarella C, Boccadoro M, Omede P, et al. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple meyloma. Bone Marrow Transplant 1993; 11: 271–7
   PubMed Web of Science ®Google Scholar
• Demirer T, Buckner CD, Gooley T, et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937–41
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Hegenbart U, Wallmeier M, et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736–44
   PubMed Web of Science ®Google Scholar
• Wahlin A, Eriksson M, Hultdin M. Relation between harvest success and outcome after autologous peripheral blood stem cell transplantation in multiple myeloma. Eur J Haemat 2004; 73: 263–88
   PubMed Web of Science ®Google Scholar
• To LB, Shepperd MK, Haylock D, et al. Single high doses of cyclophosphamide enable the collection of high numbers of stem cells from the peripheral blood. Exp Hematol 1990; 18: 442–7
   PubMed Web of Science ®Google Scholar
• Boiron J-M, Marit G, Faberes C, et al. Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte–macrophage colony-stimulating factor (GM-CSF). Bone Marrow Transplant 1993; 12: 49–55
   PubMed Web of Science ®Google Scholar
• Fitoussi O, Perreau V, Boiron JM, et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837–42
   PubMed Web of Science ®Google Scholar
• Johnson PRE, Fitzsimmons CL, Chang J, et al. Infection at the time of peripheral blood stem cell leukapheresis results in reduced granulocyte–macrophage colony forming unit yields. Br J Haematol 1995; 89: 689–90
   Google Scholar
• Jantunen E, Putkonen M, Nousiainen T, et al. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347–51
   PubMed Web of Science ®Google Scholar
• Lerro KA, Medoff E, Wu Y, et al. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplant 2003; 32: 1113–17
   PubMed Web of Science ®Google Scholar
• Russell NH, McQuaker G, Stainer C, et al. Stem cell mobilisation in lymphoproliferative diseases. Bone Marrow Transplant 1998; 22: 935–40
   PubMed Web of Science ®Google Scholar
• Kröger N, Zeller W, Fehse N, et al. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients. Br J Haematol 1998; 102: 1101–6
   PubMed Web of Science ®Google Scholar
• Lie AKW, Hui CH, Rawling T, et al. Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF. Bone Marrow Transplant 1998; 22: 853–7
   Google Scholar
• Glaspy JA, Shpall EJ, LeMaistre CF, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90: 2939–51
   PubMed Web of Science ®Google Scholar
• Weaver A, Chang J, Wrigley E, et al. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. J Clin Oncol 1998; 16: 2601–12
   PubMed Web of Science ®Google Scholar